Effect of IFN-γ on Innate Immune Cells
NCT02609932
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Chronic Granulomatous Disease
Interventions
DRUG:
Administration of drug (Interferon-gamma 1-b) subcutaneously
Sponsor
University of Colorado, Denver